News

According to new research by Katie Porter, U.S. Democratic Representative and a consumer bankruptcy law professor vying for re-election in California, the cost of a newly-launched cancer medicine in the United States was $283,000 last year, a 53% rise...

As anticipated, Congress swiftly reauthorized four important user fee programmes as part of a bill that was essential to passing in order to continue funding the federal government for another two months. The October 1 deadline for approving a...

By comparing tumour samples taken before and after treatment, a new clinical trial platform called Brain-POP (brain perioperative) will allow doctors to precisely see how a new medication therapy affects a patient's brain cancer. The project, which the Brain Cancer...

According to a recent data study by the Institute for Public Policy Research, the UK's share of worldwide research and development (R&D) spending has decreased by 5% since 2014. Despite exceeding the government's aim of 2.4% GDP for R&D expenditure,...

Gene therapy remains a topic of fascination to biopharmaceutical dealmakers despite safety worries and opposition from drug regulators, as seen by a recent flurry of deals. Eli Lilly agreed to purchase Akouos, a Boston-based company that develops gene therapies for...

One of the most difficult medical research findings, drug distribution still faces a lot of challenges, including surviving the acidic parts of the stomach, digestive enzymes, and most significantly, the mucus barrier that surrounds the digestive canal. Scientists at...

Rising energy prices in Europe run the risk of accelerating the migration of businesses necessary for the production of life-saving medications, further jeopardising the pharma supply chains that were already struggling under the worst of COVID-19. Essential medications are important...